Company news
Proqr Therapeutics N.v. (NASDAQ:PRQR) news
Proqr Therapeutics N.v. news releases on 6ix. Latest, Aug 1, 2023: ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR’s…
Press releases — page 2
ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR’s Sepofarsen and Ultevursen Ophthalmic Assets
July 31, 2023
ProQR Announces First Quarter 2023 Operating and Financial Results
May 15, 2023
ProQR Announces Annual Meeting of Shareholders to be Held May 17, 2023
April 17, 2023
ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event
March 28, 2023
ProQR Announces Successful Defense of a Key Axiomer® Patent Protecting ADAR-mediated RNA Editing
March 13, 2023
ProQR Therapeutics to Host Virtual R&D Event on March 29, 2023
February 27, 2023
ProQR Announces Conference Call to Discuss Axiomer® RNA Editing Platform
December 21, 2022
ProQR to Present its Axiomer® RNA Editing Technology at the Oligonucleotide and Peptide Therapeutics Conference (TIDES Europe) 2022
November 13, 2022
ProQR Announces Third Quarter 2022 Operating and Financial Results
November 8, 2022
ProQR Announces Second Quarter 2022 Operating and Financial Results
August 3, 2022
ProQR Announces Annual General Meeting of Shareholders and Provides Leadership Updates
May 31, 2022
ProQR to Present its Axiomer® RNA Editing Technology at the Oligonucleotide and Peptide Therapeutics Conference (TIDES USA) 2022
May 8, 2022
ProQR Announces First Quarter 2022 Operating and Financial Results
May 4, 2022
ProQR Announces Additional Sepofarsen Illuminate Trial Analyses and Provides Update on Company Strategy
April 12, 2022
ProQR Appoints John Maraganore, PhD, as Strategic Advisor to the Supervisory Board
March 6, 2022
ProQR Announces Fourth Quarter and Full Year 2021 Operating and Financial Results
February 23, 2022
ProQR Announces Top-Line Results from Phase 2/3 Illuminate Trial of Sepofarsen in CEP290-mediated LCA10
February 10, 2022
ProQR Announces Last Patient Has Completed 12 Month Visit in Phase 2/3 Illuminate Trial of Sepofarsen
January 3, 2022
ProQR Announces Amendment to Convertible Debt Financing Agreement with Pontifax Ventures and Kreos Capital
December 29, 2021
ProQR Announces First Patients Dosed in Phase 2/3 Pivotal Trials of QR-421a for USH2A Mediated Retinitis Pigmentosa
December 15, 2021
ProQR Announces Upcoming Investor Conferences in November and December
November 7, 2021
ProQR Announces Third Quarter 2021 Operating and Financial Results
November 3, 2021
ProQR Appoints Theresa Heggie as Chief Commercial Officer
October 3, 2021
ProQR Announces Conference Call to Discuss the Axiomer® RNA Editing Platform
September 7, 2021
ProQR Announces Axiomer® RNA Editing Licensing and Research Collaboration with Lilly
September 7, 2021
ProQR Announces Virtual Presentation at EURETINA 2021
September 5, 2021
ProQR Announces Second Quarter 2021 Operating and Financial Results
August 4, 2021
ProQR Announces First Quarter 2021 Operating and Financial Results
May 5, 2021
ProQR Therapeutics and Yarrow Biotechnology, an RTW Investments, LP Incubated Company, Announce Exclusive Worldwide License and Discovery Collaboration for Undisclosed Target
May 3, 2021
ProQR Announces Annual Meeting of Shareholders
April 19, 2021
ProQR Announces Publication in Nature Medicine for Sepofarsen in Leber Congenital Amaurosis 10
April 12, 2021
ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares
April 4, 2021
ProQR Prices $90 Million Underwritten Public Offering of Ordinary Shares
March 29, 2021
ProQR Announces Positive Results from Clinical Trial of QR-421a in Usher Syndrome and Plans to Start Pivotal Trials
March 23, 2021
ProQR Announces Fourth Quarter and Full Year 2020 Operating and Financial Results
February 24, 2021
ProQR Completes Enrollment of its Pivotal Trial of Sepofarsen for the Treatment of LCA10
January 6, 2021
ProQR Announces Third Quarter 2020 Operating and Financial Results
November 15, 2020
ProQR Announces Virtual Presentations at American Academy of Ophthalmology (AAO)
November 1, 2020
ProQR Appoints Naveed Shams, MD, PhD as Chief Scientific Officer
October 4, 2020
ProQR Announces Virtual Presentations at Scientific Conferences
September 23, 2020
ProQR Announces Second Quarter 2020 Operating and Financial Results
August 5, 2020
ProQR Strengthens Scientific Advisory Board with Leaders in Inherited Retinal Disease and RNA Therapy
July 20, 2020
ProQR Announces $30 Million Strategic Convertible Debt Financing Agreement with Pontifax Ventures
July 13, 2020
ProQR Announces Expert Perspectives Conference Call Series
June 11, 2020
ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen Data Through the Association for Research in Vision and Ophthalmology (ARVO)
June 7, 2020
ProQR Announces First Quarter 2020 Operating and Financial Results
May 6, 2020
ProQR Announces Positive Findings From an Interim Analysis in the Phase 1/2 trial of QR-421a for Usher Syndrome and Provides Business Update
March 30, 2020
ProQR to Present Findings from Phase 1/2 Interim Analysis of QR-421a for Usher Syndrome
March 24, 2020
ProQR Announces Fourth Quarter and Full Year 2019 Results and Provides Business Update
February 25, 2020
ProQR Receives Rare Pediatric Disease Designation from FDA for QR-421a
January 29, 2020